Contributors: Cabanillas, Maria E; Schlumberger, Martin; Jarzab, Barbara; Martins, Renato G; Pacini, Furio; Robinson, Bruce; Mccaffrey, Judith C; Shah, Manisha H; Bodenner, Donald L; Topliss, Duncan; Andresen, Corina; O'Brien, James P; Ren, Min; Funahashi, Yasuhiro; Allison, Roger; Elisei, Rossella; Newbold, Kate; Licitra, Lisa F; Sherman, Steven I; Ball, Douglas W.
نبذة مختصرة : Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 through 3 (VEGFR1-VEGFR3), fibroblast growth factor receptors 1 through 4 (FGFR1-FGFR4), platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks implicated in tumor angiogenesis. Positive phase 1 results in solid tumors prompted a phase 2 trial in patients with advanced, radioiodine-refractory, differentiated thyroid cancer (RR-DTC).
No Comments.